MHMay Hagiwara

May Hagiwara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


May Hagiwara has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US

    by Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan, Thomas Delea

    Effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients with ≥1 line of therapy (LOT) who received their first stem cell transplant (SCT) within 1 year of initial MM diagnosis were estimated using a large US claims database. Disease progression was defined as advancement to the next LOT, bone metastasis, hypercalcemia, soft tissue plasmacytoma, skeletal related events, acute kidney disease, or death within 12 months of LOT initiation. Annual HRU and costs in the first three LOTs (L1–L3) were compared for patients with versus without disease progression using inverse probability of treatment weighting to adjust for differences between groups in baseline characteristics. In all LOTs, mean annual hospitalizations and healthcare costs were greater for patients with versus without progression. Total incremental annual costs among patients with versus without progression in L1–L3 were $18,359, $87,055, and $71,917, respectively, among LOTs initiated between 2006 and 2018. In LOTs initiated between 2013 and 2018, the figures were $46,024, $100,329, and $101,942 in L1–L3, respectively. The economic burden of disease progression is substantial in this population of MM patients who underwent SCT and received systemic anti-myeloma therapy.


  • Open Access

    Real-World Treatment Patterns, Healthcare Use and Costs in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Patients in the USA

    by Deepu Madduri, May Hagiwara, Kejal Parikh, Corey Pelletier, Thomas E Delea, Arianna Kee, Ajai Chari

    Aim: To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Materials & methods: Eligible patients had ≥1 line of t... Lay abstract Treatment of multiple myeloma (MM) has evolved rapidly over recent decades, with the introduction of immunomodulatory drugs, proteasome inhibitors and the anti-CD38 monoclonal antibody...


  • Open Access

    Burden of disease progression in patients with multiple myeloma in the US

    by May Hagiwara, Sumeet Panjabi, Tom Delea, Emre Yucel, Rafael Fonseca

    Effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients with ≥1 line of therapy (LOT) and without receipt of stem cell transplant were estimated using large US claims database. Disease progression was defined as advancement to the next LOT, bone metastasis, hypercalcemia, soft tissue plasmacytoma, skeletal related events, acute kidney failure, or death within 12 months of LOT initiation. Annual HRU and costs in the first four LOTs were compared for patients with versus without progression using inverse probability of treatment weighting to adjust for differences between groups in baseline characteristics. In all LOTs, mean annual hospitalizations and healthcare costs were greater for patients with versus without progression. Total incremental annual costs among patients with versus without progression in 1LOT to 4LOT were $25,920, $30,632, $47,320, and $19,769, respectively. For MM patients receiving drug therapy, the economic burden of disease progression is substantial.


  • Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

    by May Hagiwara, Sumeet Panjabi, Arati Sharma, Thomas E. Delea

    Aim: To compare monthly healthcare resource utilization (HRU) and costs among adult patients with multiple myeloma (MM) receiving second or subsequent line of treatment (LOT) with carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone. Methods and materials: Adult MM patients who received carfilzomib or pomalidomide as second/subsequent LOT between 2006 and 2014 were selected from the MarketScan® databases. LOT was determined using Medical/pharmacy claims using a published algorithm. For each patient, first LOT with carfilzomib or pomalidomide was defined as index LOT. Patients with first LOT as index LOT, who received other chemotherapy in combination with carfilzomib or pomalidomide, or who underwent stem cell transplant (STC) during index LOT were excluded. Monthly HRU and costs during index LOT were compared using inverse probability of treatment weights (IPTW) based on propensity scores for receipt of carfilzomib estimated by logistic regression with LOT, patient demographics, Charlson index, comorbidities, pre-index healthcare cost, and receipt of prior SCT as covariates. Results: After weighting, baseline characteristics were well balanced among 114 carfilzomib and 144 pomalidomide patients. Mean (95%CI) numbers of outpatient visits per month were 7.1 (5.2 to 8.0) with carfilzomib and 4.7 (3.9 to 6.1) with pomalidomide (p = 0.006). Otherwise, there were no statistically significant differences between the groups in mean monthly HRU and costs or median time to therapy discontinuation. Mean (95%CI) monthly total healthcare costs were $19,776 (15,322 to 27,748) with pomalidomide and $17,321 (12,412 to 21,874) with carfilzomib (p = 0.522). Limitations: Comparison of carfilzomib vs. pomalidomide may be biased if there are unobserved factors not balanced by IPTW. The relatively small sample size limits the power of analyses to detect potential differences between treatment groups. Conclusions: Monthly HRU and costs are similar among patients with relapse or refractory MM patients receiving carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.


  • Open Access

    Burden of Disease Progression in Patients with Multiple Myeloma Who Have Received at Least One Line of Therapy in the US

    by May Hagiwara, Thomas Delea, Sumeet Panjabi, Emre Yucel, Rafael Fonseca

    Introduction Previous studies have documented substantial economic burden for multiple myeloma (MM) patients (pts). However, data on the economic burden of disease progression in the US are limited. In this study, we estimated effects of disease progression on healthcare resource utilization (HRU) and costs among pts with MM who have received at least one line of therapy (LOT) in the US. Methods Data from the Truven Analytics MedStat MarketScan® Commercial Claims and Encounters and Medicare and Coordination of Benefits databases were used. A retrospective incident user cohort of adult pts with a confirmed diagnosis (Dx), defined as ≥1 inpatient or ≥2 non-diagnostic outpatient claims 30-365 days apart with diagnosis, of MM who initiated a course of MM therapy during the study period (Jan 1, 2006 to Dec 31, 2016) was identified. The first date with Dx for MM was defined as the "Dx date" and LOT was identified based on a published algorithm. Pts were excluded if they had a gap in enrollment during the period beginning 6-month before the Dx date through 30-days after the first LOT (1L) initiation date, received MM therapy or unclassified antineoplastic medications before the Dx date or stem cell transplant (SCT) at any time during the study period, or had missing information required to identify LOT or assess baseline characteristics or study outcomes. The 12 months after initiation of each LOT was designated the "event identification period" for progression. Disease progression was defined as advancement to the next LOT, ICD-9/10 or CPT/HCPCS diagnosis or procedure codes indicative of bone metastasis, hypercalcemia, soft tissue plasmacytoma, skeletal related events, or acute kidney disease while off MM therapy, or death. The "event date" for progression was defined as date with evidence of progression. For each pt with progression, one pt without progression was randomly selected and assigned an index date to ensure that distribution of time from LOT initiation to event date for pts with progression was the same as that for pts without progression. For each LOT (L1-L4), annual HRU and costs from index date through disenrollment or the end of the study period were compared for pts with vs without progression using inverse probability of treatment weighting (IPTW) to adjust for differences between groups in baseline characteristics including year of index date, age, gender, region, plan type, Medicare status, comorbidities, and pre-index HRU and healthcare costs. All costs were adjusted to 2016 US dollars. In a subgroup analysis, HRU and costs were evaluated for LOTs initiated from 2013 to 2016 to reflect patterns of treatment in current era. Results Of the 28,184 adult MM pts who received one or more MM therapy during the study period, 11,179 qualified for the study, including 4468 and 6598 pts with and without progression during 1L, respectively. The corresponding numbers for 2L, 3L, and 4L were 1563 and 2207, 618 and 714, and 244 and 260, respectively. Mean age at index date was 68 years; 57% were male. After IPTW, all baseline characteristics were well balanced in all LOTs with standardized mean differences Conclusions For MM pts receiving drug therapy, the economic burden of disease progression is substantial across all LOTs and this burden is greater in the most recent era (2013 to 2016). Treatments that prevent or delay progression are likely to yield important reductions in downstream disease management costs. These savings should be considered in frameworks assessing the value of innovative treatments for MM.


  • Healthcare costs among multiple myeloma (MM) patients (Pts) without stem cell transplant (SCT).

    by Sumeet Panjabi, May Hagiwara, Arati Sharma, Yaozhu (Juliette) J. Chen, Thomas E. Delea

    8059 Background: The economic burden of MM is substantial. Treatment (Tx) costs for MM pts have been reported, however, gaps in understanding costs by line of therapy (LOT), service category, and time since Tx initiation remain. Methods: This was a retrospective observational study using the MarketScan database. Pts were adults with MM (ICD-9-CM code 203.0x) who initiated MM Tx between Jan 1, ‘06 and Dec 31, ‘14. LOT was defined by receipt of new MM Tx or a gap >90 days in MM Tx. Pts with prior SCT or insufficient continuous enrollment to determine LOT were excluded. Mean monthly healthcare costs were calculated by LOT, stratified by on- and off-tx periods, service category, and time since Tx initiation. LOT and on/off Tx periods mean costs were weighted by duration. Results: 9,464 pts met study criteria (mean age 67 y, 57% male). Mean costs during the 6 mos before 1L were $6,075/mo. On-Tx costs per mo were higher than off-tx costs in all lines. MM Tx medications represented 36%-45% of total costs across LOTs. MM complications and Tx-related AEs represented 26%-32% of total costs. Total costs per mo were highest at Tx initiation in all LOTs and declined over time. Conclusions: MM Tx medications and tx of MM complications/AEs represent the majority of healthcare costs in MM pts. Monthly MM Tx medication costs were greatest for 4L+ and monthly total costs at treatment initiation were greatest for 1L. In each LOT monthly costs declined over time. Therapies that extend PFS and the treatment-free interval may reduce the costs of MM treatment and likely defer costs of subsequent MM tx.

  • Retrospective study of frequency and cost of multiple myeloma (MM) complications and treatment (Tx) related adverse events (AEs).

    by May Hagiwara, Sumeet Panjabi, Arati Sharma, Yaozhu (Juliette) J. Chen, Thomas E. Delea

    8060 Background: Disease-related complications and Tx related AEs (collectively “events”), such as anemia, neutropenia, thrombocytopenia, bone loss and fractures, and kidney disease affect patients with MM. Real-world data on the frequency and cost of these “events” is limited. Methods: This was a retrospective observational study using the MarketScan database. Adult patients with MM (ICD-9-CM code 203,0x) who initiated MM Tx between Jan 1, 2006 and Dec 31, 2014 were identified. Patients not enrolled continuously for 180 days pre-diagnosis until 30 days after initiation of first MM Tx were excluded. Receipt of new MM Tx or gaps >90 days between MM Txs were considered new line/s of Tx (LOT). For each patient and LOT, events and associated costs while on MM Tx were identified using diagnosis/procedure and medication claim codes. The mean cost of events per LOT was calculated. Results: A total of 12,648 patients qualified for the study (mean (SD) age 65 (12.5) y, 57% male), representing 20,869 LOT (61% 1L, 24% 2L, 9% 3L, 6% 4L+). Comorbidities preceding MM Tx included chronic pain (61%), hypertension (39%), chronic renal disease (21%), diabetes (15%), solid tumor (15%), coronary heart disease (11%), and hematologic cancer other than MM (10%). Among events studied post MM Tx, skeletal-related events (SREs) were most frequent (49% per LOT across all LOTs). Other events with a frequency ≥10% per LOT included anemia (23%), 2nd primary malignancies (21%), hypertension (20%), and febrile neutropenia (FN) (12%) (Table). The frequency of events was generally highest for 1L, except for FN and non-pneumonia infections, which were more frequent in later LOTs. Among events with frequency >10%, FN was the most costly event ($24,541/LOT) followed by SRE ($12,268/LOT). Conclusions: In pts with MM, disease-related complications and Tx related AEs are frequent and their associated costs are substantial.


  • Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma

    by May Hagiwara, Michelle D. Hackshaw, Gerry Oster

    Objective: To estimate the costs of adverse events (AEs) in patients aged ≥65 years with metastatic renal cell carcinoma (mRCC). Methods: Retrospective study using the linked Surveillance, Epidemiology and End Results (SEER) Medicare database. Study subjects consisted of persons in SEER-Medicare, aged ≥65 years, with evidence of newly diagnosed mRCC between January 1, 2007 and December 31, 2007. Adverse events of interest consisted of Grade 3 or 4 toxicities that have been reported with frequency ≥5% in randomized controlled trials of sunitinib, sorafenib, bevacizumab, and pazopanib (i.e., targeted therapies for mRCC), and included abdominal pain, back pain, diarrhea, dyspnea, extremity pain, fatigue/asthenia, hand-foot syndrome, hypertension, lymphopenia, nausea/vomiting, neutropenia, proteinuria, and thrombocytopenia. Patients in SEER-Medicare with these events were identified based on ICD-9-CM diagnosis codes on Medicare claims. For each AE of interest, costs were tallied among evented patients over 30 days, beginning with the date of each patient’s first mention of the AE, and were compared with those of non-evented patients over a similar 30-day period beginning with an identical ‘shadow’ index date. Total costs were compared on an unadjusted basis and with adjustment for differences in baseline characteristics using a generalized linear model. Results: A total of 881 patients with mRCC met study entry criteria; 60% of these patients had Medicare claims with mention of one or more AEs of interest. Events occurring with frequency >20% included abdominal pain, dyspnea, and fatigue/asthenia; 10–20% of study subjects had encounters for back pain, extremity pain, and nausea/vomiting. Mean (standard deviation) total cost of care over 30 days was substantially higher among patients with AEs ($13,944 [$14,529]) compared with those without mention of these events ($1878 [$5264]). Adjusting for differences in baseline characteristics, the mean (95% confidence interval) difference in costs between evented and non-evented patients was $12,410 ($9217–$16,522). Study limitations include problems in event ascertainment due to inaccuracies in ICD-9-CM coding on Medicare claims data, and restriction of the study population to patients with metastatic involvement at initial diagnosis of RCC. Conclusions: Costs of care are substantially higher in patients aged ≥65 years with mRCC who experience AEs commonly associated with sunitinib, sorafenib, bevacizumab, and pazopanib. Efforts to prevent and/or better manage these events potentially can reduce healthcare costs.